Cargando…

Molecular Determinant of DIDS Analogs Targeting RAD51 Activity

RAD51 is the central protein in DNA repair by homologous recombination (HR), involved in several steps of this process. It is shown that overexpression of the RAD51 protein is correlated with increased survival of cancer cells to cancer treatments. For the past decade, RAD51 overexpression-mediated...

Descripción completa

Detalles Bibliográficos
Autores principales: Velic, Denis, Demeyer, Alexandre, Peterlini, Thibaut, Benhelli-Mokrani, Houda, Mathé-Allainmat, Monique, Masson, Jean-Yves, Fleury, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466854/
https://www.ncbi.nlm.nih.gov/pubmed/34576930
http://dx.doi.org/10.3390/molecules26185460
_version_ 1784573246540087296
author Velic, Denis
Demeyer, Alexandre
Peterlini, Thibaut
Benhelli-Mokrani, Houda
Mathé-Allainmat, Monique
Masson, Jean-Yves
Fleury, Fabrice
author_facet Velic, Denis
Demeyer, Alexandre
Peterlini, Thibaut
Benhelli-Mokrani, Houda
Mathé-Allainmat, Monique
Masson, Jean-Yves
Fleury, Fabrice
author_sort Velic, Denis
collection PubMed
description RAD51 is the central protein in DNA repair by homologous recombination (HR), involved in several steps of this process. It is shown that overexpression of the RAD51 protein is correlated with increased survival of cancer cells to cancer treatments. For the past decade, RAD51 overexpression-mediated resistance has justified the development of targeted inhibitors. One of the first molecules described to inhibit RAD51 was the 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid (DIDS) molecule. This small molecule is effective in inhibiting different functions of RAD51, however its mode of action and the chemical functions involved in this inhibition have not been identified. In this work, we used several commercial molecules derived from DIDS to characterize the structural determinants involved in modulating the activity of RAD51. By combining biochemical and biophysical approaches, we have shown that DIDS and two analogs were able to inhibit the binding of RAD51 to ssDNA and prevent the formation of D-loop by RAD51. Both isothiocyanate substituents of DIDS appear to be essential in the inhibition of RAD51. These results open the way to the synthesis of new molecules derived from DIDS that should be greater modulators of RAD51 and more efficient for HR inhibition.
format Online
Article
Text
id pubmed-8466854
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84668542021-09-27 Molecular Determinant of DIDS Analogs Targeting RAD51 Activity Velic, Denis Demeyer, Alexandre Peterlini, Thibaut Benhelli-Mokrani, Houda Mathé-Allainmat, Monique Masson, Jean-Yves Fleury, Fabrice Molecules Article RAD51 is the central protein in DNA repair by homologous recombination (HR), involved in several steps of this process. It is shown that overexpression of the RAD51 protein is correlated with increased survival of cancer cells to cancer treatments. For the past decade, RAD51 overexpression-mediated resistance has justified the development of targeted inhibitors. One of the first molecules described to inhibit RAD51 was the 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid (DIDS) molecule. This small molecule is effective in inhibiting different functions of RAD51, however its mode of action and the chemical functions involved in this inhibition have not been identified. In this work, we used several commercial molecules derived from DIDS to characterize the structural determinants involved in modulating the activity of RAD51. By combining biochemical and biophysical approaches, we have shown that DIDS and two analogs were able to inhibit the binding of RAD51 to ssDNA and prevent the formation of D-loop by RAD51. Both isothiocyanate substituents of DIDS appear to be essential in the inhibition of RAD51. These results open the way to the synthesis of new molecules derived from DIDS that should be greater modulators of RAD51 and more efficient for HR inhibition. MDPI 2021-09-08 /pmc/articles/PMC8466854/ /pubmed/34576930 http://dx.doi.org/10.3390/molecules26185460 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Velic, Denis
Demeyer, Alexandre
Peterlini, Thibaut
Benhelli-Mokrani, Houda
Mathé-Allainmat, Monique
Masson, Jean-Yves
Fleury, Fabrice
Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
title Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
title_full Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
title_fullStr Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
title_full_unstemmed Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
title_short Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
title_sort molecular determinant of dids analogs targeting rad51 activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466854/
https://www.ncbi.nlm.nih.gov/pubmed/34576930
http://dx.doi.org/10.3390/molecules26185460
work_keys_str_mv AT velicdenis moleculardeterminantofdidsanalogstargetingrad51activity
AT demeyeralexandre moleculardeterminantofdidsanalogstargetingrad51activity
AT peterlinithibaut moleculardeterminantofdidsanalogstargetingrad51activity
AT benhellimokranihouda moleculardeterminantofdidsanalogstargetingrad51activity
AT matheallainmatmonique moleculardeterminantofdidsanalogstargetingrad51activity
AT massonjeanyves moleculardeterminantofdidsanalogstargetingrad51activity
AT fleuryfabrice moleculardeterminantofdidsanalogstargetingrad51activity